Clinphone Share Discussion Threads

[simon gordon] 02/8/2007 12:59

I looked at them when they first floated and was put off by the high valuation and the constant need to innovate, so as to stay in the game. These factors have turned out to be true and unless you understand this sector it is a risky bet.

Good fortune.

[pugugly] 02/8/2007 12:47

Barba2:-

suggest you have a look at their site:-

Basically my imoression from their site is that they are a software company - Not a pharma trials co - Only one exec Kevin Bishop (so far as I can see with real pharma experience - SKB) 2 non execs have pharma/healthcare experience.

Details from their rns re company positioning fyi,
About ClinPhone

ClinPhone plc is a specialist Clinical Technology Organization (CTO) working
with the leading global biotech and pharmaceutical organizations. With its
corporate headquarters in Nottingham, UK, ClinPhone is the largest and most
accomplished CTO with experience in over 1950 clinical trials spanning 88
countries and 71 languages. The company's solutions enable its clients to manage
their clinical trials more effectively through the use of technology. Building
on its telephone and web-based randomization and medication management
expertise, ClinPhone can offer a wide range of innovative products covering all
aspects of a clinical trial, including Electronic Patient Reported Outcomes
(ePRO), Interactive Voice and Web Response (IVR and IWR), Patient Recruitment
Solutions, Electronic Data Capture (EDC) and Clinical Trial Management Software
(CTMS).



Let me know what you think?

[barbra2] 02/8/2007 12:08

is it time to buy?

[vision88] 01/8/2007 01:21

ClinPhone sees FY profits significantly below market expectations:


If you believe there is to be no recovery here you would im sure bail out now , but i can not see this hic up in the share price lasting much more than 6 months at the most , 2008 the share price may well be over the £2.00p mark, i remain optomistic target 2008/09 £3.50p

[cat] 31/7/2007 09:22

SNX and PRG next to go kaput.
Charts about to break down.

[pugugly] 31/7/2007 08:37

Looks like a pile of CAT_POO !!
Reading between the lines it looks as though they really messed up their quality and data controlls - They appear to have lost the confidence of some of their clients - The only thing that is missing is how much compensation they mightl have to pay (this imo) is worrying becasue by its omission or a clear statement that all problems reslulting from the foul ups are behind them could imply the reverse

[wiganer] 31/7/2007 08:24

Do I get the feeling hedgehunter and Cat just don't get along?

[cat] 31/7/2007 08:22

going splat
pile of plop.

[jsteveuk] 10/5/2007 07:27

Anyone else into CNP?



Good news this morning re. EDC with Kendle.

[hedgehunter] 03/11/2006 02:39

Very volatile this one.

[hedgehunter] 27/10/2006 08:45

Maiden profit reported at ClinPhone
an ADVFN competitor
ClinPhone moved into profit in the first half of the year, driven by growing demand for the technology its designs for drug makers to use in clinical trials.

The results, the first presented since the company floated on the London Stock Exchange in June, revealed pretax profits of £1.8m, or 2.4p per share in the six months to end-Aug. In the same period last year pretax losses came in at £90,000, or 0.14p per share.

Contracted orders increased 18% to £36.7m, helping to lift revenues 32%, to £20.7m. Average order values increased by 24%.

ClinPhone said demand for new technologies in clinical trials is growing, and estimates that 80% of the market is still using paper-based methods.

'The industry is increasingly recognising the benefits of using technology to manage the clinical trials process,' CEO, Steve Kent, said in a statement.

'The market continues to adopt technology solutions at a rapid pace and demand for our products and services continues to grow.

'We look forward to the rest of the year with confidence,' he added.

Yesterday, ClinPhone announced the acquisition of California-based Datalabs for up to 36.5 mln stg. The company designs so-called electronic data capture technology aimed at the clinical trials market.

Shares in the company, which floated at 148p, closed Thursday at 218p, giving the group a market value of £139m.





Powered by IST's

[hedgehunter] 21/10/2006 00:20

Yup and awaiting a break out.

[adascogne] 18/10/2006 09:00

More large trades going through this morning, indicated as buys. Suppose we'll find out more when results are issued.

[hedgehunter] 18/10/2006 01:37

Just needs a push and were away.

[hedgehunter] 11/10/2006 00:28

Stutering at the moment.

[adascogne] 03/10/2006 14:43

Large trades indicated as sales. Anybody got ant info?

[hyper ai] 26/9/2006 07:28

topping out on volume spike - back to 180p pdq

[hedgehunter] 25/9/2006 02:14

Back to top for klister.

[hedgehunter] 23/9/2006 10:27

A good historical piece from UK analyst.com...........

Clinphone - Buy

Clinphone's debut clearly proves that there is strong interest in the new issues market for the right sort of company. Rising 15% from a placing price of 148p on its first day of dealings, the specialist supplier of technology solutions, Clinphone, finished the day at 173p. The group successfully managed to raise 20 million of new money and place shares worth 39.1 million pounds for selling shareholders, raising a total of around 60 million pounds. However, CEO Steve Kent admits that it was extremely disheartening to launch a road show in the midst of a market fallout. 'It was worrying as companies were pulling floats by the day as we went around trying to raise money and surprisingly, institutions were more than willing to fund our IPO' says Kent. At 148p, the company came to market with a valuation of 94.1 million pounds. The placing was fully underwritten by Investec. AIM quoted HgCapital chose to realise a portion of its investment, netting 5.8 million pounds in cash. It will retain a 6.2% stake in the company. Clinphone has delivered a 37% return on investment for HG Capital over the last nine years.

Operations - Headquartered in Nottingham, the group was founded in 1993 by two doctors - Neil Rotherham and Jonathan Engler. The founders saw an opportunity to improve the clinical trials process by providing centralised support services that could be available 24 hours a day, 7 days a week, throughout the year. The original concept soon developed into a global business that now provides e-clinical solutions to 88 countries, in 77 languages, handing over 1000 clinical trials every month.

The market in which ClinPhone operates is large and growing, driven by the expanding use of technology and the increasing complexity of clinical trials. The vast majority of data collection and reporting in this market continues to be done using expensive paper based, labour intensive methods. It was estimated in 2004 that just 5-8% of all clinical trials used technology for data capture. This is forecasted to reach 40% by 2009. ClinPhone's technology reduces the cost and duration of running clinical trials and improves the accuracy and consistency of data collected. The directors believe that ClinPhone's technology could drive the transfer from paper to online in the market.

Over the last 10 years, the group has developed technology around the use of the telephone and internet to efficiently randomise patients, manage trial medications and to collect, aggregate, analyse and report clinical trial data in real time. It has a strong presence in the industry and serves 16 to 20 of the largest pharmaceutical companies by revenue. To date it has collected data from over 90,000 investigator sites.

Business Development - In the financial year to February 2006, the group brought in sales of 33.9 million pounds, an increase of 17.7% on 2005. For the period to February, the group completed 411 live studies and employed 538 employees. Pre-tax profits for the year to February 2006 came in at 947,000 pounds while profits in 2005, came in at 3.4 million pounds. The numbers have been affected by a one off charge against share based payments (the conversion of share options to shares). The charge going ahead for new share options granted is estimated to be around a million pounds, therefore pre-tax profits (after the share based payment and amortisation) could easily come in around 2 million pounds. However, if we view amortisation and share based payments as non-cash items, the group recorded an adjusted operating profit of 5.7 million pounds.
The group faces a higher US corporate tax charge of around 48% as one of its subsidiaries is based in America. The order book for the current year stands at 49.6 million pounds, underpinning sales growth for 2007. The group has net cash of just over 2 million pounds.

ClinPhone will use a large part of the funds raised to reduce its debt pile, part of it goes to HSBC and the remaining to private equity investors. This will serve to secure diversified ownership. The group does not intend to come back to the market to raise any further money and is confident of funding its operations through cash flow. With nearly 80% of the market yet to capture, Clinphone is keen on introducing new services for its customers. It intends to invest heavily in research and development and will look for paper based acquisitions to fuel growth. The group will also concentrate on increasing licensing revenue.

Management - Founders, Jonathan Engler and Neil Rotherham have sold part of their stakes for over 5 million pounds each. They currently have no involvement with the company. CEO, Steve Kent worked in various financial positions in various industries before leading an MBO in 1995 for Workplace Technologies. He joined ClinPhone in 2002. Scott Brown, CFO, qualified at Grant Thornton and subsequently worked at ABN Amro in Hong Kong. Non-Executive Chairman, Edwin Moses serves as both exec and non-executive director on the board of health related companies like Biofusion and Phoqus Group.

Investment Conclusion - Clinphone is the first to bring this technology to the clinical trials market. It is by far the largest company operating in a very niche sector across the world and faces competition only from country specific firms. The next few years will see the company gaining market share across the world. The analysts and the company were reluctant to give us an indication of sales or profits for the next few years. If we ignore amortisation and share based payments and assume Clinphone can bring in post tax profits of around 6 million pounds in the year to 2007 (and we believe our estimates are conservative), it trades on a current year PE of 16. This could easily fall to a single digit PE in 2008. At 173p, we believe Clinphone is a buy offering real value in the current new issues market.

Contact Details - Investec - 020 7597 5197

[hedgehunter] 22/9/2006 23:08

Well I certainly rate it a buy and may even add.

[blank frank] 16/9/2006 21:51

Please note the following new thread which may be of interest:
"Telecom Shares You Should Buy: The Tips League Table"

[adascogne] 13/9/2006 13:03

Yes got in at 2.12 just think it's got potential, good sector and good management

[hedgehunter] 12/9/2006 23:21

These are moving up nicely. Anyone else in them here?.

[hedgehunter] 27/6/2006 00:45

Over the last 10 years, the group has developed technology around the use of the telephone and internet to efficiently randomise patients, manage trial medications and to collect, aggregate, analyse and report clinical trial data in real time. It has a strong presence in the industry and serves 16 to 20 of the largest pharmaceutical companies by revenue. To date it has collected data from over 90,000 investigator sites.

In the financial year to February 2006, the group brought in sales of 33.9 million pounds, an increase of 17.7% on 2005. For the period to February, the group completed 411 live studies and employed 538 employees. Pre-tax profits for the year to February 2006 came in at 947,000 pounds while profits in 2005, came in at 3.4 million pounds. The numbers have been affected by a one off charge against share based payments (the conversion of share options to shares). The charge going ahead for new share options granted is estimated to be around a million pounds, therefore pre-tax profits (after the share based payment and amortisation) could easily come in around 2 million pounds. However, if we view amortisation and share based payments as non-cash items, the group recorded an adjusted operating profit of 5.7 million pounds.